LBTN

[sebfr]

LBTN has changed of trendline...Good positive direction...We can expect news great !!! ::)advance..

Today price is at 0.017
There is a resistance at 0.025
sure Target : 0.075
Stop loss : 0.07
Ratio : 441:142 = 3.10

Fundamentals :
Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN - http://finance.yahoo.com/q?s=LBTN.PK ) Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company.

[sebfr]

Lifeline Biotechnologies Successfully Completes Testing of MastaScope Diagnostic Product in China
10/28/05       

RENO, Nev., Oct 28, 2005 (BUSINESS WIRE) --
Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN) today announced that the Company has successfully completed the testing of MastaScope(TM) at three different hospitals in China. The MastaScope(TM) product provides sharp, clear, and accurate imagery of the intraductal breast tissues and abnormalities.

The MastaScope(TM) was tested on 17 patients by Chinese surgeons under the direction of Dr. Pedro Escobar. Dr. Escobar is a Fellow in Breast and Gynecologic Oncology at the Cleveland Clinic Foundation. The surgeons were able to insert the MastaScope(TM), which is a micro-endoscope, through the patient's nipple so the surgeon can examine the interior of the milk duct during the examination. Lifeline Biotechnologies already has been issued the Import Registration Number by the Chinese SDA, which is the equivalent to the American FDA.

"The MastaScope(TM) was very well received by chief breast surgeons at the Zheijang Province People's Hospital, as well as the China-Japan Friendship Hospital and Beijing Third University Hospital. All the scopes and duct excisions were successful," stated Dr. Pedro Escobar.

"The completion of the testing of the MastaScope(TM) will enable us to continue with our strategy in entering the Chinese and Asian markets," stated Jim D. Holmes, CEO of Lifeline Biotechnologies, Inc.

[setravis]

Nice.......
I will applaud this. .......Next time tap me on the shoulder!

[gmarc66]

Ok Seb_spa..i'm tapping u on the shoulder

The last few days i noticed this fluctuate up and down between about .01 and .014..wondering if its because of this news out this a.m.

what do u think...good time to get in?

2005-11-17 08:30:06 
Lifeline Biotechnologies Files 510(k) Application with the Food and Drug Administration for the MastaScope(TM) 

Business Editors / Health/Medical Writers

RENO, Nev.--(BUSINESS WIRE)--Nov. 17, 2005--
Lifeline Biotechnologies (Pink Sheets: LBTN) announced
today that the Company has filed a 510(k) Pre-market Notification with
the FDA, for the MastaScope(TM) product line. The FDA approval process
is expected to take several months to complete.
The MastaScope(TM) is a microendoscope that is utilized by
physicians to observe the interior of women's breast milk ducts when
examining for abnormalities, in particular, nipple discharge. The
majority of breast cancers originate in the milk ducts. It is
anticipated that this product and process of examination, will assist
in the early detection of breast cancer and holds the prospect of
reducing unnecessary exploratory surgeries.
Dr. Mokbel, Lifeline principal investigator has stated that "For
every 100 nipple discharge cases, one instance of breast cancer is
found." The prospect of the MastaScope holds the potential of reducing
unnecessary exploratory surgeries.
"We knew that eventually we would need to complete this 510(k)
once the MastaScope(TM) advanced from research and development to
marketing and sales. We are very excited about the potential future of
the MastaScope(TM)," stated Jim Holmes, CEO of Lifeline
Biotechnologies

[sebfr]

Good time to entry again...Julia

MA50 as support and good trendline at 0.0090 and good retracement > 0.80
The risk = possible cup and handle...So price go down before to go up
The risk = 0.009 (0.014 = 55%) -> target at 0.030 (142%) Ratio = 142 / 55 =2.58...

For me, i still wait for a pullback at about 0.010-0.011...A new test of support !

[gmarc66]

PPS is very low now at .0075...wonder if this news will make it rise again.

2005-12-07 08:30:02 
Lifeline Biotechnologies Reduces Debt By $250,000 


Business Editors / Health/Medical Writers

RENO, Nev.--(BUSINESS WIRE)--Dec. 7, 2005--
Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN)
announced today that the Company will reduce their debt by
approximately $250,000 by forgiving past salaries owed to management.
These reductions will be ongoing, equivalent to an annual Company
savings of approximately $150,000 to $200,000 in operating expenses.
This is a first step in a process designed to increase shareholder
value. Additionally, Lifeline Biotechnologies' management is retiring
approximately 51 Million Shares and will reissue stock options at .05
cents per share.
Due to the increase in the outstanding shares, as a result of
shares having been issued principally to acquire financing required
for operations and product development, the company has committed to a
program designed to enhance shareholder value through a comprehensive
strategy, starting with the reduction of the Company's debt. The debt
reduction will enable Lifeline to better implement their business
strategy.
"We believe that this reduction of debt will add substantial
value for our shareholders," said Jim Holmes, CEO of Lifeline
Biotechnologies, Inc. "This is the first step in a restructuring
process. This reduction of debt and stock retirement is designed to
also compensate for any additional shares that may be issued in order
to continue funding the Company. We firmly believe that this is in the
best interests of both our shareholders and the company."

[sebfr]

We can play again at this level...
Indeed, price is close to his support...

[gmarc66]

This divy news this a.m made the stock go nuts, went over 200%, now on a pullback...glta

Wednesday, March 29 2006 8:14 AM, EST


Lifeline Biotechnologies Announces a Stock Dividend for Its Shareholders


RENO, Nev.--(BUSINESS WIRE)--March 29, 2006-- Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN) today announced a common stock dividend which will be issued to its shareholders of record as of April 14, 2006. The stock dividend will total approximately 50 Million unrestricted shares of LBTN. Lifeline Biotechnologies shareholders are expected to receive approximately one and a half shares of LBTN for each ten shares already owned on the record date.

"This stock dividend to shareholders is a reward for their continued support as we focus on the increased marketing efforts of our MastaScope(TM) and the development of our First Warning System(TM) and OvaScope(TM). We are very pleased to be in a position to give back to our loyal shareholders and show our appreciation," stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

About Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's technologies, designed to assist in the early detection of cancers, deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used to assist in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: http://www.lbti.com.

[gmarc66]

Tuesday, April 11 2006 11:12 AM, EST

Today Is the Final Day to Qualify for Lifeline Biotechnologies' Stock Dividend

RENO, NV -- (MARKET WIRE) -- 04/11/06 -- Lifeline Biotechnologies, Inc. (OTC: LBTN) announced that today is the final day for investors to qualify for the Company's Stock Dividend. Lifeline Biotechnologies recently announced that May 1, 2006 will be the date on which the stock dividend will be issued to its shareholders of record as of April 14, 2006.

The dividend will total an estimated 50 Million unrestricted shares of LBTN. Lifeline Biotechnologies' shareholders are expected to receive approximately one and a half shares of LBTN for every ten shares already owned on the record date.

"This is a very exciting time for our Company and our shareholders. We are very pleased by the response that we have received from investors and we look forward to the continued growth and development of our products and our Company," stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.